Antihypertensive Drugs

Correct Answer

A — Combined alpha and beta-adrenergic receptor antagonist

Rationale

Labetalol is a combined alpha and beta-adrenergic receptor antagonist. Metoprolol is a selective beta-1 adrenergic receptor antagonist. Methyldopa is a centrally acting alpha-2 adrenergic receptor agonist. Nifedipine is a dihydropyridine calcium channel blocker.

Correct Answer

C — Centrally acting alpha-2 adrenergic receptor agonist

Rationale

Methyldopa is a centrally acting alpha-2 adrenergic receptor agonist. Hydralazine is a direct arteriolar vasodilator. Prazosin is a selective alpha-1 adrenergic receptor antagonist. Losartan is an angiotensin receptor blocker.

Correct Answer

B — Anticonvulsant

Rationale

Magnesium sulfate is classified as an anticonvulsant when used in severe preeclampsia, not as an antihypertensive. Nifedipine is an antihypertensive agent. Terbutaline is a tocolytic agent. Aspirin is an anti-platelet agent.

Correct Answer

D — Renin-angiotensin-aldosterone system inhibitors

Rationale

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers both belong to the broader category of renin-angiotensin-aldosterone system inhibitors. Methyldopa is a centrally acting antihypertensive. Hydralazine is a direct vasodilator. Metoprolol is a beta-adrenergic receptor antagonist.

Correct Answer

A — Dihydropyridine calcium channel blockers

Rationale

Nifedipine is a dihydropyridine calcium channel blocker. Verapamil and diltiazem are non-dihydropyridine calcium channel blockers.

Correct Answer

C — Angiotensin converting enzyme inhibitors

Rationale

Enalapril is an angiotensin converting enzyme inhibitor. Valsartan is an angiotensin receptor blocker. Aliskiren is a direct renin inhibitor. Spironolactone is a mineralocorticoid receptor antagonist.

Correct Answer

B — Loss of deep tendon reflexes is the earliest clinical sign of magnesium toxicity, occurring at serum levels of 7 to 10 mEq/L — the infusion should be reduced or stopped and respiratory rate must be monitored closely because respiratory depression is the next step in the toxicity sequence

Rationale

The magnesium toxicity sequence follows a predictable ladder based on rising serum concentrations. The therapeutic range for seizure prophylaxis is 4 to 7 mEq/L. Loss of the patellar deep tendon reflex — clinically the most accessible reflex — is the earliest clinical sign of toxicity and occurs at serum levels of 7 to 10 mEq/L, just above the therapeutic range. This is why hourly deep tendon reflex assessment is a mandatory monitoring requirement during magnesium infusion. Loss of reflexes is a warning that progression toward respiratory depression is possible; the infusion rate should be reduced or the infusion stopped and the clinical team must immediately increase monitoring frequency of respiratory rate, which must be maintained at or above 12 breaths per minute. Respiratory depression occurs at levels of 10 to 13 mEq/L. Cardiac arrest occurs above 15 mEq/L. The antidote for magnesium toxicity is calcium gluconate 1 gram intravenous (10 milliliters of 10 percent solution) administered over 3 minutes — calcium competes with magnesium at excitable membranes and rapidly reverses neuromuscular and cardiac toxicity.

Correct Answer

D — Failure of trophoblastic invasion of spiral arteries causes placental ischemia, which triggers release of anti-angiogenic factors that inhibit vascular endothelial growth factor, producing systemic endothelial dysfunction with vasoconstriction, increased vascular permeability, and platelet activation

Rationale

The central pathophysiological event in preeclampsia is abnormal placentation. Normally, trophoblast cells invade the maternal spiral arteries and remodel them into wide, low-resistance vessels that supply the placenta with high-flow, low-pressure blood. When this invasion fails, the spiral arteries remain narrow and high-resistance, reducing placental perfusion and causing placental ischemia. The ischemic placenta releases anti-angiogenic factors — most prominently soluble fms-like tyrosine kinase-1 — which circulate systemically and bind to and neutralize vascular endothelial growth factor, a critical endothelial survival and function factor. Loss of vascular endothelial growth factor signaling in the maternal systemic vasculature produces diffuse endothelial dysfunction: vasoconstriction raises blood pressure, increased vascular permeability causes protein to leak into urine and fluid to shift into tissues, and platelet and coagulation system activation predisposes to thrombosis. This sequence explains why preeclampsia is a systemic disease affecting kidney, liver, brain, and placenta — not merely a hypertensive disorder.

Correct Answer

A — The fetal kidney requires angiotensin II signaling for normal renal development; blockade causes fetal renal dysgenesis, which eliminates fetal urine production, causing oligohydramnios, which then prevents normal fetal lung development (pulmonary hypoplasia) because amniotic fluid is needed for lung inflation and growth

Rationale

The fetal renin-angiotensin-aldosterone system is not merely a blood pressure regulator in the fetus — it is an essential developmental signaling system for renal organogenesis. Angiotensin II acting through angiotensin II type 1 receptors is required for normal differentiation of nephrons, formation of the collecting duct system, and maturation of glomerular structure. When angiotensin converting enzyme inhibitors or angiotensin receptor blockers cross the placenta and suppress this system, fetal renal development is disrupted, causing renal tubular dysplasia or agenesis. Without functioning fetal kidneys, fetal urine production ceases — and after the second trimester, fetal urine is the primary source of amniotic fluid. The result is oligohydramnios (severely reduced amniotic fluid). Amniotic fluid is required for normal fetal lung development: the fetus inhales and exhales amniotic fluid, and the mechanical distension of the airways is a signal for bronchial and alveolar development. Without this fluid, pulmonary hypoplasia occurs — the lungs fail to develop enough surface area for gas exchange after birth, causing neonatal respiratory failure. Limb contractures from oligohydramnios and calvarial hypoplasia are additional manifestations.

Correct Answer

C — No — magnesium sulfate is an anticonvulsant and causes only a modest, insufficient blood pressure reduction; antihypertensive therapy with labetalol, nifedipine, or hydralazine must proceed in parallel to control the blood pressure

Rationale

Magnesium sulfate is classified as an anticonvulsant, not an antihypertensive. Its mechanism in preeclampsia is blockade of N-methyl-D-aspartate glutamate receptors in the central nervous system, reducing cortical excitability and preventing seizures. While magnesium does have some calcium channel antagonist properties in vascular smooth muscle that produce a mild secondary blood pressure reduction, this effect is modest and insufficient for antihypertensive management — it cannot reliably bring severe-range blood pressure below target. Treating blood pressure with magnesium alone would leave the patient at risk for maternal hemorrhagic stroke and placental abruption from uncontrolled severe hypertension. Labetalol (intravenous or oral), nifedipine (oral), and hydralazine (intravenous) are the dedicated antihypertensive agents used in parallel with magnesium. The distinction between magnesium sulfate and antihypertensives is a common source of clinical confusion and a tested concept on assessments of obstetric pharmacology.

Correct Answer

B — Start at 20 mg over 2 minutes; if inadequate, give 40 mg after 10 minutes, then 80 mg every 10 minutes as needed; maximum cumulative dose per episode is 300 mg; onset is 5 to 10 minutes

Rationale

The intravenous labetalol protocol for acute severe hypertension in pregnancy uses an escalating bolus regimen: 20 mg administered slowly over 2 minutes as the initial dose. If blood pressure remains in the severe range after 10 minutes, 40 mg is given; if still inadequate after another 10 minutes, 80 mg is given, with 80 mg doses repeatable at 10-minute intervals — up to a maximum cumulative dose of 300 mg per episode. Onset of action is 5 to 10 minutes with a duration of 3 to 6 hours. This protocol is specifically designed to allow titration while monitoring for maternal bradycardia (avoid maternal heart rate below 60 beats per minute) and fetal heart rate changes. Labetalol is favored in obstetric emergencies because its dual alpha-beta blockade avoids reflex tachycardia, maintains uteroplacental perfusion better than pure vasodilators, and provides a titratable response with extensive clinical experience in this setting. The escalating dose sequence — 20/40/80 mg — is a tested pharmacological detail in obstetric medicine.

Correct Answer

D — Mobilization of extravascular fluid (particularly pronounced after magnesium sulfate infusion) into the intravascular compartment expands plasma volume, while loss of placental vasodilatory prostaglandins removes a vasodilatory stimulus — both raise blood pressure

Rationale

Two concurrent physiological events drive the blood pressure surge that commonly occurs on postpartum days 3 to 5. First, the extravascular fluid that accumulated during pregnancy — and was further expanded by the capillary leak of preeclampsia and by magnesium sulfate-associated fluid shifts — begins to mobilize back into the intravascular space as endothelial function starts to recover. This autotransfusion effect expands plasma volume and raises cardiac output and blood pressure. Second, the placenta is a major source of vasodilatory prostaglandins that lower peripheral vascular resistance during pregnancy; delivery removes this prostaglandin source abruptly, eliminating its vasodilatory contribution. Women with severe preeclampsia are at particular risk because they have greater capillary leak during their admission and may have received large volumes of intravenous fluids. Blood pressure monitoring is required for at least 72 hours after delivery in women with severe preeclampsia, and postpartum eclampsia can occur up to 48 hours — and rarely up to 4 weeks — after delivery.

Correct Answer

A — The contraindicated route is sublingual (under the tongue), which produces an unpredictable and precipitous blood pressure drop; swallowing the immediate-release capsule produces a more gradual oral absorption — this route is acceptable in the obstetric acute protocol with a slower and more predictable onset of 20 to 30 minutes

Rationale

The apparent contradiction resolves when the route of administration is clarified. When immediate-release nifedipine is bitten or pierced and the contents absorbed sublingually, the drug reaches systemic circulation within minutes, producing a rapid, high plasma peak and an abrupt, unpredictable blood pressure drop — a dangerous pattern that has been associated with maternal and fetal adverse events including stroke and fetal distress. This sublingual route is contraindicated. When the same immediate-release capsule is swallowed intact, gastrointestinal absorption is slower and more predictable, producing peak blood pressure reduction at 20 to 30 minutes — a clinically acceptable time course for managing acute severe hypertension in the obstetric setting where the drug can be redosed if needed. The American College of Obstetricians and Gynecologists acute hypertension protocol specifies oral nifedipine 10 milligrams swallowed, not administered sublingually, with repeat dosing after 20 to 30 minutes if blood pressure remains in the severe range. For chronic antihypertensive management in pregnancy, only extended-release formulations are used.

Correct Answer

C — Treatment is recommended, targeting systolic 120 to 159 and diastolic 80 to 104 millimeters of mercury — treating mild chronic hypertension reduced adverse pregnancy outcomes by 18 percent in a randomized trial without increasing the risk of small-for-gestational-age births; targets below 120/80 are avoided because uteroplacental perfusion is not autoregulated and excessive lowering reduces fetal blood flow

Rationale

A randomized trial of mild chronic hypertension in pregnancy compared treating to below 140/90 millimeters of mercury against waiting until blood pressure reached 160/105 before treating. Active treatment from the outset reduced the composite primary outcome — including preeclampsia with severe features, medically indicated preterm birth before 35 weeks, placental abruption, and perinatal death — by 18 percent. The trial also found no increase in small-for-gestational-age births, the key safety concern about antihypertensive use in pregnancy. Based on this evidence, current guidance recommends treating when systolic reaches 140 or diastolic reaches 90 millimeters of mercury in pregnant patients with chronic hypertension. The target blood pressure range — systolic 120 to 159 and diastolic 80 to 104 — reflects the important lower boundary: unlike in other vascular beds, uteroplacental blood flow has no autoregulatory capacity. If maternal blood pressure falls too low, placental perfusion falls proportionally, risking fetal hypoxia and growth restriction. This is why targeting below 120/80 is specifically avoided in pregnancy.

Correct Answer

D — Discontinue lisinopril immediately and switch to labetalol, long-acting nifedipine, or methyldopa — angiotensin converting enzyme inhibitors disrupt fetal renal development through all three trimesters and carry a black box warning for use in pregnancy

Rationale

Angiotensin converting enzyme inhibitors are absolutely contraindicated throughout all three trimesters of pregnancy. The fetal renin-angiotensin-aldosterone system is required for normal renal organogenesis — disrupting it causes fetal renal dysgenesis, oligohydramnios from absent fetal urine production, and pulmonary hypoplasia from the resulting lack of amniotic fluid needed for lung development. The Food and Drug Administration black box warning requires immediate discontinuation on confirmed pregnancy. Angiotensin receptor blockers carry the same contraindication through the same mechanism and are not an acceptable substitute — both classes must be stopped. The patient's blood pressure of 136/84 should be managed with labetalol (oral), long-acting nifedipine (extended-release oral), or methyldopa, all of which have established safety records in pregnancy. Women of childbearing potential on angiotensin converting enzyme inhibitors or angiotensin receptor blockers should be counseled about this contraindication and have a pregnancy-safe alternative identified before conception.

Correct Answer

B — This is magnesium toxicity — reduced urine output has caused drug accumulation since magnesium is renally excreted; stop the infusion immediately and administer calcium gluconate 1 gram intravenously over 3 minutes as the antidote

Rationale

This patient has three clinical signs of magnesium toxicity: lethargy, respiratory rate of 10 breaths per minute (below the minimum required rate of 12 breaths per minute), and absent patellar deep tendon reflexes. The precipitating factor is reduced urine output of 15 milliliters per hour — well below the minimum required 25 milliliters per hour — which indicates inadequate renal excretion of magnesium. Since magnesium is cleared entirely by the kidney, oliguria allows serum magnesium to rise into toxic territory. Absent deep tendon reflexes indicate levels in the 7 to 10 mEq/L range; respiratory depression at this patient's rate indicates levels approaching 10 to 13 mEq/L. The infusion must be stopped immediately and calcium gluconate 1 gram intravenous (10 milliliters of a 10 percent solution) administered over 3 minutes. Calcium directly antagonizes magnesium at neuromuscular junctions and cardiac membrane channels, rapidly reversing toxicity. If respiratory depression is severe, mechanical ventilation may be needed while calcium takes effect. This case illustrates why hourly deep tendon reflex checks, respiratory rate monitoring, and urine output measurement are mandatory during magnesium infusion.

Correct Answer

A — Preferred agents: intravenous labetalol, oral nifedipine (swallowed), or intravenous hydralazine; agents to avoid: angiotensin converting enzyme inhibitors and angiotensin receptor blockers (fetal renal harm) and sodium nitroprusside (fetal cyanide toxicity)

Rationale

Severe-range hypertension in pregnancy (systolic at or above 160 or diastolic at or above 110 millimeters of mercury) requires antihypertensive treatment within 30 to 60 minutes to prevent maternal hemorrhagic stroke and placental abruption. The three first-line acute antihypertensive options are intravenous labetalol (escalating bolus protocol: 20/40/80 milligrams), oral nifedipine immediate-release swallowed (10 milligrams, repeated in 20 to 30 minutes if needed — not sublingual), and intravenous hydralazine (5 to 10 milligrams, repeated every 20 to 30 minutes). All three are considered acceptable by the American College of Obstetricians and Gynecologists. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers are absolutely contraindicated — they disrupt fetal renin-angiotensin-aldosterone system-dependent renal development and must never be used in any trimester. Sodium nitroprusside releases cyanide during its metabolism, and the fetal liver has limited capacity to metabolize cyanide — it is avoided unless no other option exists. Sublingual nifedipine is also contraindicated due to its precipitous, unpredictable blood pressure drop.

Correct Answer

C — Labetalol, long-acting nifedipine, and methyldopa are compatible with breastfeeding; captopril and enalapril are acceptable in full-term neonates; angiotensin receptor blockers have insufficient breastfeeding safety data and are generally avoided — losartan should not be restarted while she breastfeeds

Rationale

The three antihypertensives used as first-line agents in pregnancy — labetalol, long-acting nifedipine, and methyldopa — are also well-established as breastfeeding-compatible based on studies showing low breast milk transfer and absence of adverse neonatal effects. Among angiotensin converting enzyme inhibitors, captopril and enalapril specifically have been shown to transfer minimally into breast milk at concentrations below the threshold for pharmacological effect in full-term neonates; they can therefore be used postpartum in women with full-term neonates who require renin-angiotensin-aldosterone system inhibition for conditions such as diabetic nephropathy or heart failure. Angiotensin receptor blockers present a different situation: adequate breastfeeding safety data are lacking for this class, and given the uncertainty, they are generally avoided during breastfeeding. Losartan, her pre-pregnancy agent, should not be restarted while she breastfeeds. Safety in pregnancy does not automatically confer breastfeeding safety — the pharmacokinetics of drug transfer into breast milk and infant drug metabolism must be independently evaluated for each agent.